Industry Urges Caution Over Japan HTA Plans
This article was originally published in PharmAsia News
Executive Summary
Japan may have decided to dip an exploratory toe in the waters of health technology assessment, but the research-based pharma industry is continuing to voice early caution over potential shortcomings in methodology and expertise, and to stress the need for a holistic approach.
You may also be interested in...
Pricey New HCV, Cancer Drugs Push Up Japan’s Health Care Costs
Japan has reported big rises in drug costs covered by its national health insurance scheme, driven in large part by hepatitis C and cancer, adding weight to ongoing discussions of possible new cost containment measures.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.